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GENERAL COMMENTS
The aim of the manuscript "The effect of luseogliflozin and alphaglucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomized controlled trial" is to describe the protocol that will evaluate the efficacy of luseogliflozin in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction. Comments 1. The study protocol is well built and described but, because the end point is a surrogate end point I think is not corrected to use the term "clinical efficacy"; the possible reduction in BNP may not corrispond to a clinical benefit or a reduction in clinical events. The exact term could be that the study will evaluate the drug's ability to reduce BNP in heart failure patients with preserved EF 2. Chronic Heart Failure and preserved Ejection Fraction (EMPEROR-Preserved)". The primary outcome in these studies are "hard end points" and they will probably provide important results about the efficacy of these drugs on the mortality and morbidity of patients with preserved EF heart failure and diabetes.
they will probably provide important results about the efficacy of these drugs on the mortality and morbidity of patients with preserved EF heart failure and diabetes. I think that, even if is correct to underline the importance to have physiopathological data, these studies should also be mentioned in the discussion.
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GENERAL COMMENTS
The manuscript reports the design of a clinical trial aimed to explore the effect of a SGLT2 inhibitor vs an alpha-glucosidase inhibitor in patients with heart failure but preserved ejection fraction. The study has been already approved by an ethic committee and the trial has been registered in the UMIN Clinical Trials Registry. I suggest to register the trial also in clinicaltrial.gov in order to increase the visibility of the study.
For what concern the manuscript i have only a couple of suggestions:
-The figure resuming the study design and the flow followed of the patients (figure 1) lacks a legend (for the colors) and a detailed description. Considering that the treatment will be applied for 12 weeks, while some outcome measures will be performed also at 24 weeks, it is unclear if the drug will be withdrawn in this remaining period or if routine clinical practice will be applied (e.g. in case of a benefit of the drugs in terms of HbA1 reduction the drug should not be discontinued, especially in patients with previous HbA1>8). Please specify the path of the patients in this time period.
-In the abstract it is stated: "The key secondary endpoints are the change from baseline in the ratio of early mitral inflow velocity to mitral annular early diastolic velocity..after 12 weeks of treatment". However, in the table resuming the assessments (figure 2) it is reported that at 12 and 24 weeks the echocardiography will be performed only if possible. Please be sure that an echo is planned, otherwise these secondary endpoints should be removed. Also, even if BNP is a valuable marker for heart failure, ejection fraction (EF) should be considered also as an endpoint (even if it is unlikely to observe a consistent change in such short time period), especially considering that to select and enroll the patients population you use EF and not BNP.
Minor point:
-I can't see all the laboratory analysis that will be performed because the 
VERSION 1 -AUTHOR RESPONSE
For Reviewer #1
1. The study protocol is well built and described but, because the end point is a surrogate end point I think is not corrected to use the term "clinical efficacy"; the possible reduction in BNP may not corrispond to a clinical benefit or a reduction in clinical events. The exact term could be that the study will evaluate the drug's ability to reduce BNP in heart failure patients with preserved EF.
Response: We thank this comment pointing out an inadequate description. We corrected the description as follows: The MUSCAT-HF trial is an ongoing, multi-center, randomised controlled trial designed to investigate the drug efficacy of luseogliflozin to reduce BNP in T2DM patients with HFpEF. (Page 13, Paragraph 7, Line 242-243)
2. This aspect of the surrogate end point should be emphasized in the discussion explaining what are the limitations and advantages of these type of end points.
Response: We thank this comment. We added a sentence to discuss our study endpoints as follows: Although our study focused on BNP as surrogate endpoint for worsening of heart failure, the results will provide the evidence for the drug efficacy of SGLT2 inhibitor on pathophysiological aspects in those patients. With Chronic Heart Failure and preserved Ejection Fraction (EMPEROR-Preserved)". The primary outcome in these studies are "hard end points" and they will probably provide important results about the efficacy of these drugs on the mortality and morbidity of patients with preserved EF heart failure and diabetes. they will probably provide important results about the efficacy of these drugs on the mortality and morbidity of patients with preserved EF heart failure and diabetes. I think that, even if is correct to underline the importance to have physiopathological data, these studies should also be mentioned in the discussion.
Response: We thank this suggestive comment. We added a sentence to discuss these studies as follows: Further, several clinical trials to investigate the effect of SGLT2 inhibitors in cardiovascular clinical hard endpoints in HFpEF patients with T2DM are ongoing (EMPEROR-Preserved; ClinicalTrials.gov Identifier: NCT03057951 and DELIVER; ClinicalTrials.gov Identifier: NCT0361921).
(Page 14, Line 262-265)
For Reviewer #2 -The figure resuming the study design and the flow followed of the patients (figure 1) lacks a legend (for the colors) and a detailed description. Considering that the treatment will be applied for 12 weeks, while some outcome measures will be performed also at 24 weeks, it is unclear if the drug will be withdrawn in this remaining period or if routine clinical practice will be applied (e.g. in case of a benefit of the drugs in terms of HbA1 reduction the drug should not be discontinued, especially in patients with previous HbA1>8). Please specify the path of the patients in this time period.
